The Impact of Efflux Pump Inhibitors on the Activity of Selected Non-Antibiotic Medicinal Products against Gram-Negative Bacteria

Molecules. 2017 Jan 11;22(1):114. doi: 10.3390/molecules22010114.

Abstract

The potential role of non-antibiotic medicinal products in the treatment of multidrug-resistant Gram-negative bacteria has recently been investigated. It is highly likely that the presence of efflux pumps may be one of the reasons for the weak activity of non-antibiotics, as in the case of some non-steroidal anti-inflammatory drugs (NSAIDs), against Gram-negative rods. The activity of eight drugs of potential non-antibiotic activity, active substance standards, and relevant medicinal products were analysed with and without of efflux pump inhibitors against 180 strains of five Gram-negative rod species by minimum inhibitory concentration (MIC) value determination in the presence of 1 mM MgSO₄. Furthermore, the influence of non-antibiotics on the susceptibility of clinical strains to quinolones with or without PAβN (Phe-Arg-β-naphthylamide) was investigated. The impacts of PAβN on the susceptibility of bacteria to non-antibiotics suggests that amitriptyline, alendronate, nicergoline, and ticlopidine are substrates of efflux pumps in Gram-negative rods. Amitriptyline/Amitriptylinum showed the highest direct antibacterial activity, with MICs ranging 100-800 mg/L against all studied species. Significant decreases in the MIC values of other active substances (acyclovir, atorvastatin, and famotidine) tested with pump inhibitors were not observed. The investigated non-antibiotic medicinal products did not alter the MICs of quinolones in the absence and in the presence of PAβN to the studied clinical strains of five groups of species.

Keywords: Gram-negative bacteria; MDR; PAβN; drugs; efflux; efflux pump inhibitor; medicinal products; non-antibiotics; quinolones.

MeSH terms

  • Acyclovir / pharmacology
  • Alendronate / pharmacology
  • Amitriptyline / pharmacology*
  • Anti-Bacterial Agents / pharmacology*
  • Atorvastatin / pharmacology
  • Dipeptides / pharmacology*
  • Drug Combinations
  • Drug Resistance, Multiple, Bacterial / drug effects
  • Drug Resistance, Multiple, Bacterial / genetics
  • Escherichia coli / drug effects
  • Escherichia coli / growth & development
  • Escherichia coli / metabolism
  • Famotidine / pharmacology
  • Genes, MDR / drug effects*
  • Klebsiella pneumoniae / drug effects
  • Klebsiella pneumoniae / growth & development
  • Klebsiella pneumoniae / metabolism
  • Magnesium Sulfate / pharmacology
  • Microbial Sensitivity Tests
  • Nicergoline / pharmacology
  • Pseudomonas aeruginosa / drug effects*
  • Pseudomonas aeruginosa / growth & development
  • Pseudomonas aeruginosa / metabolism
  • Quinolones / pharmacology
  • Salmonella / drug effects
  • Salmonella / growth & development
  • Salmonella / metabolism
  • Ticlopidine / pharmacology

Substances

  • Anti-Bacterial Agents
  • Dipeptides
  • Drug Combinations
  • Quinolones
  • phenylalanylarginine-naphthylamide
  • Amitriptyline
  • Famotidine
  • Magnesium Sulfate
  • Atorvastatin
  • Nicergoline
  • Ticlopidine
  • Alendronate
  • Acyclovir